WALTHAM, Mass --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, reported purchases during July 2015 of
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, reported that Quell, launched in June
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, announced today the launch of the Quell
The Only FDA Cleared Wearable for 24/7 Chronic Pain Relief BOSTON --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell Wearable Pain Relief Technology will be featured at the APMA Annual Meeting this week in Orlando, Florida .
Quell Commercial Launch Milestone Achieved; Strong Early Shipments WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), today reported financial and business highlights for the quarter ended June 30, 2015 . The Company operates in two primary markets - wearable
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2015 second quarter financial results before the opening of the market on July 22, 2015 . The Company will host a conference call at 8:00 a.m., Eastern Time on July 22, 2015 to discuss its
The Only FDA Cleared Wearable for 24/7 Chronic Pain Relief BOSTON --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced the full commercial launch of Quell , which is now available on the Company's product website at QuellRelief.com and at select physicians' offices.
Quell ™ Wearable Pain Relief and DPNCheck ® Neuropathy Test to be Featured WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians better manage chronic
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq:NURO) today reported that it has closed its previously announced underwritten public offering. The Company sold 147,000 units, with each unit consisting of one share of Series B convertible preferred stock and 99 warrants exercisable for
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq:NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today reported that it has begun to ship
